ZEGFROVY is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 ...
Galderma Delivers Net Sales of 4.765 B USD in the First Nine Months, Up 25.1% at Constant Currency Year-on-Year, and Raises Full-Year Net Sales Guidance .bwalignc { text-align: center; ...
When you are concerned about gray hair on your nape or nape line, it is recommended that you first check how much is visible ...
Angela Fitch, MD, co-founder and chief medical officer of Knownwell, discussed GLP-1 access strategies and a proposed ...
When red bumps that look like acne or pimples appear on the nape of your neck, it becomes impossible to tell if they are acne ...
Sanofi will now work with provincial, territorial and federal drug programs to support access to the treatment for eligible ...
Dupixent is also indicated as an add-on maintenance treatment with intranasal corticosteroids in adult patients with severe ...
Aurobindo Pharma launched ADQUEY in the US to treat atopic dermatitis. Learn about this specialty drug move, Q1 financials, ...
The DecisionDx-Melanoma 31-GEP test recently released top data from the largest prospective GEP study. The study was originally highlighted at EADV in Vienna. It stratified patients and met its ...
Boston biotech Bambusa files for Nasdaq IPO (BBTX) to fund eczema and inflammation trials, backed by RA Capital, KKR-linked Dawn and other major investors.
Pfizer Inc. presented detailed results from an ongoing Phase 2 study investigating tilrekimig (PF-07275315) in adults with moderate-to-severe atopic dermatitis (AD). The study met its primary endpoint ...
Regeneron Pharmaceuticals (NASDAQ:REGN) and Sanofi said they are expanding their long-running collaboration to develop and commercialize next-generation medicines for type 2 inflammatory diseases, add ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results